Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials-Reference-Cited by-同舟云学术

Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials

Published:2020-03-03 Issue:6 Volume:76 Page:843-850
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Lasala Ruggero^ORCID,Logreco Andrea,Romagnoli Alessia,Santoleri Fiorenzo,Musicco Felice,Costantini Alberto

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00228-020-02850-y.pdf

Reference31 articles.

1. Woodcock J (2018) Expediting drug development for serious illness: trade-offs between patient access and certainty. Clin Trials 15(3):230–234

2. Morant AV, Vestergaard HT (2018) European marketing authorizations granted based on a single pivotal clinical trial: the rule or the exception? Clin Pharmacol Ther 104(1):169–177

3. Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N (2016) Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open 6(6):e011666

4. Hilal T, Sonbol MB, Prasad V (2019) Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncol 5(6):887–892

5. EMA. Conditional marketing authorisation. https://www.ema.europa.eu/en/human- regulatory/marketing-authorisation/conditional-marketing-authorisation. Published 2017. Accessed June 2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer;European Journal of Clinical Pharmacology;2024-01-20

2. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020;JAMA Network Open;2022-08-10

3. Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer;European Journal of Cancer;2021-07

4. What can heart failure trialists learn from oncology trialists?;European Heart Journal;2021-06-02

5. Activity of Povidone in Recent Biomedical Applications with Emphasis on Micro- and Nano Drug Delivery Systems;Pharmaceutics;2021-05-04